Agenus | AGEN - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
AbbVie USD 645M 69M 2026-03
Agenus USD 16.02M 2.85M 2025-12
Amgen USD 657M 4M 2026-03
AstraZeneca USD 484M 181M 2025-12
Bristol-Myers Squibb USD 411M 21M 2026-03
CSL USD 215M 111M 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Gilead Sciences USD 240M 15M 2026-03
GlaxoSmithKline GBP 167M 21M 2026-03
Glaxosmithkline GBP 177.95M 6.05M 2025-09
Incyte USD 569K 13K 2026-03
Intrexon USD 2K 5K 2024-06
J&J USD 43M 25M 2026-03
Jiangsu Hengrui CNY 254.59M 253.85M 2025-09
Karyopharm Therapeutics USD 12.62M 1.24M 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
Merck EUR 104M 17M 2026-03
Merck USD 479M 67M 2026-03
Northwest Biotherapeutics USD 1.52M 276K 2024-03
Novartis USD 343M 39M 2026-03
Novavax USD 5.82M 342K 2025-12
Pfizer USD 671M 40M 2026-03
Regeneron Pharmaceuticals USD 12.9M 700K 2026-03
Rigel Pharmaceuticals USD 2.06M 31K 2024-09
Sangamo BioSciences 97.56M 11.39M 2025-06
Veracyte USD 2K 1000 2023-12